Dr. Newton Howard

ni2o, Inc.

Dr. Newton Howard is the founder of ni2o, Inc, which is developing a novel, artificial-intelligence driven brain-computer interface to treat a wide range of debilitating neurological disorders and to improve cognitive and athletic performance.

His career spans academia, the U.S. military and the private sector. A prolific scientific author and inventor, he is highly skilled in moving research from the lab to military and commercial applications, including technology you may use daily such as wireless hot spots, Google Earth and Google Translate.

Dr. Howard is a professor at Oxford and Georgetown. He directs the Computational Neurosciences Lab at Oxford and the Synthetic Intelligence Lab at MIT.

dont miss

The Future of Brain Sensors and Implants

Dr. Howard will speak about implantable computing and decoding the language of the brain to treat patients with traumatic brain injuries and neurodegenerative disorders and the eventual use for preemptive treatment as well as to enhance natural human capabilities.

EVEN MORE SEMINARS

  • Bethel Osuagwu, Derek Jones: Speaking at the European Neurological Convention

    Bethel Osuagwu, Derek Jones
    Stoke Mandeville Spinal Research

    Assessment of the orthotic and long-term functional gain of the SEM Glove in people with chronic spinal cord injury

  • Victor A Vargas Vega: Speaking at the European Neurological Convention

    Victor A Vargas Vega
    VX9 International Consulting Group

    Decoding the Face… Application of Facial Coding in real life.

  • Tamsin Reed: Speaking at the European Neurological Convention

    Tamsin Reed
    Wellington Hospital, London

    Maximising outcomes using advanced technology in Neurological Rehabilitation.

  • Professor Jeremy  Hobart: Speaking at the European Neurological Convention

    Professor Jeremy Hobart
    Plymouth University

    TBC

  • Heather Campbell: Speaking at the European Neurological Convention

    Heather Campbell
    Guys & St Thomas’ NHS Foundation trust

    Navigating pathways for “invisible patients” in South East London